391 results on '"Michel, Marc"'
Search Results
2. Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study
3. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
4. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study
5. Hospitalization for Infection in Patients with Primary Autoimmune Hemolytic Anemia Treated with Rituximab. a Prospective, Nationwide Cohort Study in France
6. Platelet count threshold for hemorrhage in patients with immune thrombocytopenia treated with antiplatelet agents
7. AUTOIMMUNE HEMOLYTIC ANEMIA DURING PREGNANCY AND PUERPERIUM: AN INTERNATIONAL MULTI-CENTER EXPERIENCE
8. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia
9. Severe chronic primary neutropenia in adults: report on a series of 108 patients
10. Multirefractory Primary Immune Thrombocytopenia in Adults: Prevalence and Burden. Results from the Carmen-France Registry
11. Drug-Induced Autoimmune Hemolytic Anemia: Detection of New Signals in the World Pharmacovigilance Database and Risk Assessment in a Nationwide Cohort Study in France
12. Long-Term Outcome of Adolescents and Young Adults with Chronic Primary Immune Thrombocytopenia (ITP)
13. Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)
14. Autoimmune Hemolytic Anemia during Pregnancy or Post-Partum: An International Multi-Center Experience
15. Platelet Count Threshold Associated with Bleeding in Adult Patients with Immune Thrombocytopenia Treated with Antiplatelet Drugs. Results from the Carmen-France Registry
16. Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)
17. Autoimmune hemolytic anemia during pregnancy and puerperium: an international multicenter experience
18. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients
19. Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia
20. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group
21. De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring
22. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines
23. Splenectomy for Primary Immune Thrombocytopenia Revisited at the Era of Thrombopoietin Receptor Agonists: New Insights for an Old Treatment
24. A Retrospective Multicenter Case Study Evaluating the Characteristics, Management and Outcome of Acquired Amegakaryocytic Thrombocytopenia
25. Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study)
26. Adolescents and Young Adults with Immune Thrombocytopenia (ITP): A Project of the Carmen-France and Parc-ITP Registry
27. Characteristics and Outcome of Adults with Severe Autoimmune Hemolytic Anemia Admitted in Intensive Care Unit: Results from a Large French Observational Study
28. Surveillance Program of Romiplostim Use Connected to Pregnancy
29. Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study
30. Causes and Circumstances of Death: Analysis in 266 Sickle Cell Adult Patients
31. IgA-mediated human autoimmune hemolytic anemia as a result of hemagglutination in the spleen, but independent of complement activation and FcαRI
32. Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children
33. A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults
34. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases
35. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
36. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study
37. Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
38. Outcome of Immune Thrombocytopenia in Pregnancy: A French Nationwide Prospective Multicenter Observational Case-Control Study
39. Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up
40. Efficacy and Safety of a Combination of Thrombopoietin Receptor Agonist with an Immunosuppressant Therapy for the Management of Multirefractory Adult ITP: Results from a Retrospective, Multicenter, Observational Study
41. Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress
42. Risk Factors of Neonatal Immune Thrombocytopenia in Pregnant Women Previously Diagnosed with ITP: Results from a French Nationwide Prospective Study
43. Biosimilar of Rituximab for the Treatment of Primary Immune Thrombocytopenic Purpura : A Case-Control Study
44. Evans' Syndrome in Adults: An Observational Multicentre Study
45. Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study
46. Causes of Death in 198 Sickle Cell Adult Patients: Old and New Trends
47. Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody
48. Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia
49. Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia
50. Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.